Healthcare Industry News: HSMN NewsFeed
News Release - October 11, 2010
IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe(R) Device for Eye SurgeryMOUNTAIN VIEW, Calif., Oct. 11 -- (Healthcare Sales & Marketing Network) -- IRIDEX Corporation (Nasdaq:IRIX ) today announced commercial availability of a new family of Adjustable & Intuitive EndoProbe laser handpieces for use with the Company's laser platforms in vitreoretinal surgery. The Adjustable & Intuitive Laser Probes speed up treatments by allowing continuous, intuitive adjustment of the fiber optic over a wide range of angles for full coverage of the peripheral retina without requiring removal and reinsertion of the probe from the eye or requiring frequent adjustments of laser power settings. In addition, its innovative design and construction allows surgeons to treat further away from the retina and/or at a lower power setting.
"The introduction of this product under a newly issued U.S. patent reinforces our strategy of building upon our position as the global leader in laser delivery instrumentation and to continue to increase the value of our consumable instrumentation line," said Theodore A. Boutacoff, President and CEO.
"We will continue to focus on introducing new products that differentiates us from our competitors and leverage our existing sales channel to increase our revenues."
This product is protected by U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of consumable medical devices already in the IRIDEX product line, collectively identified and sold as Adjustable and Intuitive EndoProbeŽ laser handpieces.
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit our website at http://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the Company's plans to focus on new products and increase revenues. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2010 which was filed with the Securities and Exchange Commission and in our Quarterly Report on Form 10-Q for the fiscal quarter ended July 3, 2010. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.